PROphet®
For biology-driven,
informed decision-making

PROphet®
For biology-driven,
informed decision
making

PROphet®
For biology-driven,
informed decision-making

PROphet®
For biology-driven,
informed decision
making

PROphet® is a unique plasma proteomics profiling platform that accurately guides first-line anti-PD-1/PD-L1 treatment decisions for advanced, unresectable NSCLC patients

A new dimension to personalization

PROphet® combines bioinformatics, system biology, proteomic pattern recognition and machine learning to provide clinicians with actionable clinical insights, optimal therapy choices, and a better understanding of their patients’ personalized cancer dynamics.

PROphet® scans approximately 7,000 proteins in a patient's blood plasma and delivers a report predicting their likelihood of obtaining clinical benefit from anti-PD-1/PD-L1 treatment plans.

Currently available for the following indications

Non-Small Cell
Lung Cancer (NSCLC)
Melanoma
(Coming Soon)

With just one pre-treatment blood test, PROphet® produces a
personalized report answering an important clinical question:

What is the optimal first line of therapy for this patient?
We apply proprietary computational models that analyze the proteomic patterns in the patient’s plasma and identify those proteins that are associated with resistance to treatment.

How it works

Simple pre-treatment
blood test collected
at patient's own home
High-throughput
proteomic assay
Bioinformatics and
machine learning
The PROphet® Report with
analysis of clinical benefit
and actionable insights is
sent to physician
The blood sample is analyzed and processed at OncoHost’s
CLIA-registered* and COLA-accredited lab in Cary, North Carolina
*CLIA number: 34D2250951

Clinical Validation

The PROphet® model was developed using patient blood samples and clinical data collected within the framework of an ongoing clinical study conducted by OncoHost (PROPHETIC; NCT04056247). In brief, pre-treatment blood samples were collected from 630 advanced stage non-small cell lung cancer (NSCLC) patients, out of which 545 were undergoing anti-PD-1/PD-L1 therapy with or without chemotherapy, and 85 were being treated with chemotherapy.

Patient clinical data were recorded, including demographics, clinical characteristics, and clinical benefit. Blood plasma was profiled by the SomaScan® Discovery Assay v4.1, and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. Specifically, a proprietary prediction algorithm was developed to identify proteomic patterns associated with clinical benefit from anti-PD-1/PD-L1 treatment.

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
27518
T. (855) 950-2112
E. [email protected]

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
3057324
T. +972 485 37558
E. [email protected]